It should come as little surprise that the rise in decentralized trials (DCTs) and increase in study complexities have magnified performance demands across clinical trial teams.
A recent survey by Ernst & Young found 50% of clinical trials will be hybrid or decentralized by 2024. This is welcome news for sponsors
By all accounts, the cost of clinical trials continues to rise. We hear reasons that include increasing protocol complexity, patient recruitment struggles, or regulatory challenges. And we shrug our shoulders. Most of us accept these rising costs and obstacles as a given.
But - why?
If you could predict the future problems